ASCO-GI – ALX resurrects evorpacept
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.
ASCO-GI – Exelixis’s son of Cabometyx disappoints
The company might need something better to replace its ageing blockbuster.
Innate challenges Pfizer in Nectin-4
While Cogent joins the FGFR party.
ASCO-GI – no masking Xilio's setback
Poor efficacy clouds prospects for the company's "improved" Yervoy.
Novartis’s post-Pluvicto plan materialises
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
Zai Lab looks towards an accelerated pathway
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
Atara still can't get across the US finish line
Just when investors thought things couldn't get any worse, they do.
Licensed assets enter the clinic
The latest first-in-human trial initiations include projects licensed in by Gilead and Context.
Nuvalent sets out its two-pronged strategy
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
Regeneron’s lung cancer Lag3 lag
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
